July 2019 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2016/17 Invitation to Tender dated 3 November 2016, 2017/18 Invitation to Tender dated 2 November 2017, and the 2018/19 In
Some of the pharmaceuticals that will be delisted when the period of Sole Subsidised Supply/Hospital Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to notify any changes to PHARMAC and the Pharmacy Guild of New Zealand by:
- For new listings, by 4pm on the 14 August 2019 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link). Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest). PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2017/18 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2021
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of listing |
Date of reference pricing of other listed brands |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|---|
|
Povidone iodine |
Antiseptic soln 10% 15 ml bottle |
$0.19 |
$3.83 |
Riodine |
1 October 2019 |
n/a |
1 March 2020 |
Betadine |
|
Povidone iodine |
Antiseptic soln 10%, 100 ml bottle |
$1.28 |
$2.55 |
Riodine |
1 September 2019 |
n/a |
1 February 2020 |
Betadine |
|
Povidone iodine |
Antiseptic soln 10%, 500 ml bottle |
$6.20 |
$5.40 |
Riodine |
1 October 2019 |
1 December 2019 |
1 March 2020 |
Betadine |
|
Rivastigmine |
Patch 4.6 mg per 24 hour; 30 patches |
$90.00 |
$48.75 |
Generic Partners |
1 January 2020 |
1 March 2020 |
1 June 2020 |
Exelon |
|
Rivastigmine |
Patch 9.5 mg per 24 hour; 30 patches |
$90.00 |
$48.75 |
Generic Partners |
1 January 2020 |
1 March 2020 |
1 June 2020 |
Exelon |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Date of subsidy change |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Povidone iodine |
Antiseptic soln 10%, 100 ml bottle |
$2.95 |
$2.55 |
Riodine |
1% |
1 September 2019 |
1 November 2019 |
3. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand (Supplier) |
DV Limit |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Povidone iodine |
Antiseptic soln 10%, 500 ml bottle |
$6.20 |
$5.40 |
Riodine |
1% |
1 October 2019 |
1 March 2020 |
Betadine |
|
Rivastigmine |
Patch 4.6 mg per 24 hour; 30 patches |
$90.00 |
$48.75 |
Generic Partners |
1% |
January 2020 |
1 March 2020 |
Exelon |
|
Rivastigmine |
Patch 9.5 mg per 24 hour; 30 patches |
$90.00 |
$48.75 |
Generic Partners |
1% |
January 2020 |
1 March 2020 |
Exelon |
4. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Povidone iodine |
Antiseptic soln 10%, 15 ml bottle |
$3.83 |
Riodine |
1% |
1 October 2019 |
1 March 2020 |
|
Teicoplanin |
Inj 400 mg vial; 1 vial pack |
$56.50 |
Teicoplanin Mylan |
1% |
1 February 2020 |
1 July 2020 |
2018/19 Tender – Sole Subsidised Supply Status or Hospital Supply Status applies until 30 June 2022
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
5. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand |
Date of subsidy change |
Sole Subsidised Supply date |
|---|---|---|---|---|---|---|
|
Ethinyloestradiol and norethisterone |
Tab 35 mcg with norethisterone 1 mg and 7 inert tab; 84 tablet blister pack |
$6.62 |
$6.95 |
Brevinor 1/28 |
1 October 2019 |
1 March 2020 |
|
Levonorgestrel |
Tab 30 mcg; 84 tablet blister pack |
$6.62 |
$16.50 |
Microlut |
1 February 2020 |
1 May 2020 |
6. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Sole supply brand (Supplier) |
Date of listing |
Sole Subsidised Supply date |
Brand (Supplier) affected by reference pricing and delisting |
|---|---|---|---|---|---|---|---|
|
Metoclopramide hydrochloride |
Inj 5 mg per ml, 2 ml ampoule; 10 amp pack |
$13.56 |
$9.50 |
Pfizer |
1 October 2019 |
1 January 2020 |
Link Healthcare |
|
Paraffin |
White soft; 500 g pot |
$3.58 |
$4.99 |
healthE |
1 November 2019 |
1 April 2020 |
PSM (API) |
|
Paraffin |
White soft; 2500 g bucket |
$20.20 |
$19.99 |
healthE |
1 November 2019 |
1 April 2020 |
IPW |
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
7. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|---|
|
Metoclopramide hydrochloride |
Inj 5 mg per ml, 2 ml ampoule; 10 amp pack |
$13.56 |
$9.50 |
Pfizer |
1% |
1 October 2019 |
1 January 2020 |
8. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Ketamine |
Inj 1 mg per ml, 100 ml bag; 10 bag pack |
$27.00 (per 1) |
$270.00 (per 10) |
Biomed |
1% |
1 September 2019 |
1 February 2020 |
Biomed (1 pack) |
|
Ketamine |
Inj 10 mg per ml, 10 ml syringe; 5 syringe pack |
$14.00 (per 1) |
$70.00 (per 5) |
Biomed |
1% |
1 September 2019 |
1 February 2020 |
Biomed (1 pack) |
9. Tenders awarded to pharmaceuticals where no brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
New |
Hospital supply brand |
DV |
Listing date |
Hospital Supply Status date |
|---|---|---|---|---|---|---|
|
Ethinyloestradiol and norethisterone |
Tab 35 mcg with norethisterone 1 mg and 7 inert tab; 84 tab blister pack |
$6.95 |
Brevinor 1/28 |
1% |
1 October 2019 |
1 March 2020 |
|
Levonorgestrel |
Tab 30 mcg; 84 tablet blister pack |
$16.50 |
Microlut |
1% |
1 February 2020 |
1 May 2020 |
|
Nimodipine |
Tab 30 mg; 100 tab blister pack |
$350.00 |
Nimotop |
1% |
1 February 2020 |
1 July 2020 |
|
Nimodipine |
Inj 200 mcg per ml, 50 ml vial; 1 vial pack |
$67.50 |
Nimotop |
1% |
1 February 2020 |
1 July 2020 |
|
Paraffin |
White soft; 500 g pot |
$4.99 |
healthE |
1% |
1 November 2019 |
1 April 2020 |
|
Sucrose |
Oral liq 25%; 25 ml bottle |
$13.00 |
Biomed |
1% |
1 September 2019 |
1 February 2020 |
Tender declines - Products where no tender is to be awarded for Sole Subsidised Supply Status or Hospital Supply Status
PHARMAC has resolved not to award tenders for Sole Subsidised Supply Status or Hospital Supply Status for the following products listed in:
- the 2016/17 Invitation to Tender, dated 3 November 2016,
- the 2017/18 Invitation to Tender, dated 2 November 2017, and
- the 2018/19 Invitation to Tender, dated 1 November 2018
2016/17 invitation to tender
|
Chemical name |
Line item |
|---|---|
|
Amantadine hydrochloride |
Cap 100 mg |
|
Benzylpenicillin sodium [Penicillin G] |
Inj 3 g |
|
Chlorhexidine with ethanol |
Soln 2% with ethanol 70%, non-staining (pink) 100 ml |
|
Chlorhexidine with ethanol |
Soln 2% with ethanol 70%, non-staining pink (pack size less than 50 ml) |
|
Chlorhexidine with ethanol |
Soln 2% with ethanol 70%, staining (red) 100 ml |
|
Chlorhexidine with ethanol |
Soln 2% with ethanol 70%, staining red (pack size less than 50 ml) |
|
Ephedrine |
Inj 3 mg per ml, 10 ml prefilled syringe |
|
Hyoscine n-butylbromide |
Inj 20 mg, 1 ml |
|
Mebeverine hydrochloride |
Tab 135 mg |
|
Tenoxicam |
Inj 20 mg |
|
Zinc |
Paste (pack size 50 g or less) |
2017/18 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Ambrisentan (current access) |
Tab 10 mg |
|
Ambrisentan (current access) |
Tab 5 mg |
|
Ambrisentan (widened access) |
Tab 10 mg |
|
Ambrisentan (widened access) |
Tab 5 mg |
|
Budesonide (current access) |
Cap 3 mg modified release |
|
Budesonide (widened access) |
Cap 3 mg modified release |
|
Bupivacaine hydrochloride |
Inj 0.25%, 20 ml sterile pack |
|
Bupivacaine hydrochloride |
Inj 0.5%, 10 ml sterile pack |
|
Bupivacaine hydrochloride |
Inj 0.5%, 20 ml sterile pack |
|
Calamine |
Ltn, BP |
|
Chlorhexidine gluconate |
Crm 1% obstetric |
|
Chlorhexidine gluconate |
Lotn 1% obstetric |
|
Chlorhexidine gluconate |
Soln 4% |
|
Daptomycin |
Inj 350 mg – 500 mg |
|
Hydrocortisone butyrate |
Lipocream 0.1% (pack size greater than 30 g) |
|
Hydrogen peroxide |
Crm 1% |
|
Metaraminol tartrate |
Inj 0.5 mg per ml, 20 ml prefilled syringe |
|
Metaraminol tartrate |
Inj 1 mg per ml, 10 ml prefilled syringe |
|
Metaraminol tartrate |
Inj 10 mg per ml, 1 ml |
|
Mixed salt solution for eye irrigation |
Eye irrigation solution calcium chloride 0.048% with magnesium chloride 0.03%, potassium chloride 0.075%, |
|
Povidone iodine |
Oint 10% |
|
Tobramycin |
Solution for inhalation 60 mg per ml, 5 ml |
2018/19 Invitation to Tender
|
Chemical name |
Line item |
|---|---|
|
Bupivacaine hydrochloride |
Inj 1.25 mg per ml, 200 ml bag |
|
Bupivacaine hydrochloride |
Inj 2.5 mg per ml, 20 ml ampoule |
|
Capsaicin |
Crm 0.025% |
|
Capsaicin |
Crm 0.075% |
|
Gemcitabine hydrochloride |
Inj 1 g |
|
Gemcitabine hydrochloride |
Inj 200 mg |
|
Lidocaine [Lignocaine] hydrochloride |
Inj 1%, 20 ml, sterile pack |
|
Lidocaine [Lignocaine] hydrochloride |
Inj 2%, 20 ml, sterile pack |
|
Magnesium sulphate |
Inj 0.4 mmol per ml, 250 ml bag |
|
Metronidazole |
Inj 5 mg per ml, 100 ml bag |
|
Misoprostol |
Tab 200 mcg |
|
Noradrenaline |
Inj 0.1 mg per ml, 100 ml bag |
|
Oestradiol |
TDDS 100 mcg per day |
|
Oestradiol |
TDDS 50 mcg per day |
|
Ondansetron hydrochloride |
Inj 2 mg per ml, 2 ml |
|
Ondansetron hydrochloride |
Inj 2 mg per ml, 4 ml |
|
Paliperidone |
Inj 25 mg syringe |
|
Paliperidone |
Inj 50 mg syringe |
|
Paliperidone |
Inj 75 mg syringe |
|
Paliperidone |
Inj 100 mg syringe |
|
Paliperidone |
Inj 150 mg syringe |
|
Piperacillin with tazobactam |
Inj 4 g with tazobactam 500 mg |
For products included in the 2017/18 and 2018/19 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to PHARMAC Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made.
If you have any queries regarding this notification, please contact PHARMAC on 0800 66 00 50.